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IgG4-related disease (IgG4-RD) is a systemic disease characterized by the elevation of serum IgG4 and
inﬁltration of IgG4-positive plasma cells in multiple target organs, including the pancreas, kidney, biliary
tract and salivary glands. In contrast, Mikulicz’s disease (MD) has been considered a subtype of Sjögren’s
syndrome (SS) based on histopathological similarities. However, it is now recognized that MD is an IgG4-
RD distinguishable from SS and called as IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS).
Regarding immunological aspects, it is generally accepted that CD4þ T helper (Th) cells play a crucial role
in the pathogenesis of SS. Since it is well known that IgG4 is induced by Th2 cytokines such as interleukin
(IL)-4 and IL-13, IgG4-DS is speculated to be a unique inﬂammatory disorder characterized by Th2 im-
mune reactions. However, the involvement of Th cells in the pathogenesis of IgG4-DS remains to be
clariﬁed. Exploring the role of Th cell subsets in IgG4-DS is a highly promising ﬁeld of investigation. In
this review, we focus on the selective localization and respective functions of Th cell subsets and discuss
the differences between SS and IgG4-DS to clarify the pathogenic mechanisms of these diseases.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license. Sjögren’s syndrome (SS) is an autoimmune disease character-
ized by lymphocytic inﬁltration into the salivary and lacrimal
glands with concomitant autoantibody production and destruc-
tion of the glandular tissue. Patients typically experience symp-
toms of dry mouth (xerostomia) and dry eyes (keratoconjunctivitis
sicca). Because of its characteristic lymphocytic inﬁltration and
destruction of the salivary and lacrimal glands, SS is considered to
be an ideal disease for studying patterns of cytokine production at
the site of organ-speciﬁc autoimmune damage [1]. SS occurs alone
as primary SS, or as secondary SS when underlying other con-
nective tissue diseases [2]. Immunohistochemical studies
demonstrated that the salivary glands are predominantly inﬁl-
trated by CD4þ T helper (Th) cells at an early stage of SS, and these
cells are therefore thought to play a crucial role in the induction
and/or maintenance of the disease [3]. In advanced stage, B cells
predominate and these inﬁltration extends to occupy the acinar: þ81 92 642 6386.
mura).
Ltd.Open access under CC BY license. epithelium and further progress to hypergammaglobulinemia and
B cell lymphoma [4]. Recent studies have suggested a central role
of the epithelium in orchestrating the immune reaction by
expressing HLA antigens, adhesion and costimulatory molecules,
cytokines, and chemokines. Therefore, SS has been proposed as an
etiological term “autoimmune epithelitis” [4e7], and it is of in-
terest to examine the involvement of interaction between CD4þ Th
cells and the epithelium in the initiation and progression of the
disease process. Th cell populations comprise functionally distinct
subsets characterized by speciﬁc patterns of cytokines and tran-
scription factors. At least six Th subsets exist: Th0, Th1, Th2, Th17,
regulatory T (Treg), and follicular helper T (Tfh) cells [8], which are
suggested to be involved in the pathogenesis of SS [9e12].
On the other hands, Mikulicz’s disease (MD) has been consid-
ered to be a subtype of SS based on histopathological similarities
between the two diseases [13]. However, MD has a number of
differences compared with typical SS including: 1) difference of
gender distribution (MD occurs in both men and women, while SS
occurs mainly in women); 2) persistent enlargement of lacrimal
and salivary glands; 3) normal or mild salivary secretion dysfunc-
tion; 4) good responsiveness to corticosteroid treatment; 5)
hypergammaglobulinemia and low frequency of anti SS-A and SS-B
antibodies by serological analyses; and 6) multiple GC formation in
M. Moriyama et al. / Journal of Autoimmunity 51 (2014) 81e8882glandular tissue (Table 1). Previously, we reported that SS was
characterized by periductal lymphocytic inﬁltration with atrophy
or severe destruction of the acini, while MD showed non-periductal
lymphocytic inﬁltration with hyperplastic GCs and mild destruc-
tion of the acini (Fig.1) [14]. Fifteen of 66 patients with SS (23%) and
12 of 20 patients with MD (60%) showed ectopic GC formation in
labial salivary glands (LSGs). Patients with MD showed a signiﬁ-
cantly higher frequency, higher number and larger size of
GCs compared with SS patients [15]. In addition, Yamamoto et al.
[16e18] reported that patients with MD had elevated levels of
serum IgG4 and inﬁltrating IgG4-positive plasma cells in the gland
tissues. Similar ﬁndings have been observed in autoimmune
pancreatitis (AIP) [19], sclerosing cholangitis [20], tubulointerstitial
nephritis [21], Ridel’s thyroiditis [22] and Küttner’s tumor [23].
These diseases are now referred to as IgG4-related disease (IgG4-
RD) [24,25]. We recently described the concept of IgG4-RD and
provided up-to-date information regarding this emerging disease
entity [26]. Recent studies have referred to MD as IgG4-related
dacryoadenitis and sialoadenitis (IgG4-DS) [15,27] (Table 2).
IgG4 molecules are symmetrical homobivalent antibodies that
can exchange half-molecules (heavy and light chain) speciﬁc for
two different antigens (“Fab-arm exchange”), which results in
losing the ability to cross-link antigens and to form immune
complexes [28]. In addition, IgG4 also can bind the Fc fragment of
other IgG molecule, particularly other IgG4 molecules (“FceFc in-
teractions”). These IgG4 FceFc interactions proceed to Fab-arm
exchange reaction and may contribute to the anti-inﬂammatory
activity, which includes a poor ability to induce complement and
cell activation caused by low afﬁnity for C1q (Fig. 2) [29]. Another
characteristic is that IgG4 is a Th2-dependent immunoglobulin and
has lowafﬁnity for its target antigen. interleukin (IL)-4 directs naive
human B cell immunoglobulin isotype switching to IgG4 and IgE
production [30]. We previously reported that peripheral CD4þ Th
cells from patients with IgG4-DS revealed a deviation in the Th1/
Th2 balance to Th2 and elevated expression of Th2-type cytokines
[15,31,32]. Therefore, IgG4-DS is suggested to have a Th2-
predominant phenotype. This review article will emphasize
recent studies seeking to understand the role of Th cell subsets in
primary SS and IgG4-DS.
1. Cytokine proﬁles of CD4D Th cells
1.1. Th1/Th2 paradigm
Th1 cells support cell-mediated immunity and produce IL-2,
interferon (IFN)-g, and tumor necrosis factor (TNF)-a, which
induce inﬂammatory responses responsible for killing intracellular
parasites and perpetuating autoimmune responses. However,
excessive inﬂammatory responses can lead to uncontrolled tissueTable 1
Clinical and laboratory ﬁndings of Sjögren’s syndrome (SS) and IgG4-related
dacryoadenitis and sialoadenitis (IgG4-DS). x IgG4 positive plasma cells/IgG posi-
tive plasma cells >50%.
SS IgG4-DS
Peak age of onset 40’s and 50’s 60’s
Sex Male Female Male & Female
Salivary secretion dysfunction Moderate or severe None or mild
Glandular swelling Recurrent Persistent
Sialography Apple-tree sign Parenchymal defect
IgG4þ plasma cell inﬁltrationx Positive Negative
Serum IgG Often high High
Serum IgG4 Normal High
Serum complement Normal Often low
Anti SS-A/SS-B antibody (þ) High rate Rare
Antinuclear antibody (þ) Often Raredamage. Th2 cells produce IL-4, IL-5, and IL-13, which provide help
for humoral immunity and promote IgE secretion and eosinophilic
responses. Th2 responses can counteract Th1-mediated micro-
bicidal action. Thus, the Th1/Th2 balance plays an important role in
immunoregulation. In contrast, Th0 cells are characterized by the
production of both Th1 and Th2 cytokines and are considered
precursors of Th1 and Th2 cells. Several studies have revealed that
autoimmune diseases are caused by disruption to the Th1/Th2
balance [33,34]. The relationship of Th1/Th2 imbalance to the
pathogenesis of SS has been widely investigated. Polarized Th1
responses were associated with the immunopathology of SS [9].
High numbers of IFN-g-positive CD4þ T cells were detected in the
salivary glands of SS patients and intracellular cytokine analysis
demonstrated the polarization of Th cells to a Th1 phenotype [35].
Furthermore, we reported that IL-2 and IFN-g were consistently
detected in all SS patients, while IL-4 and IL-5 were only detected in
patients with high levels of B cell accumulation in the salivary
glands [10,36]. Recently, Theander et al. [37] reported that the
detection of GC-like structures (B cell accumulation) in LSG biopsy
specimens from primary SS patients could be used as a highly
predictive and easy-to-obtain marker for B cell lymphoma devel-
opment. Taken together, these studies suggest that Th1 cytokines
are essential for the induction and/or maintenance of SS, whereas
Th2 cytokines may be involved in disease progression, especially
local B cell activation. Our clinical data was demonstrated that Th1
and Th2 cytokine concentrations were signiﬁcantly higher in saliva
from SS patients than from controls, and the levels of Th2 cytokines
were closely associated with increased lymphocytic accumulation
in LSGs. Thus, the measurement of cytokines in saliva may be useful
for diagnosis and to reveal disease status [12].
IgG4-DS patients frequently have a history of bronchial asthma
and allergic rhinitis with severe eosinophilia and elevated serum IgE
levels [38]. It is well known that allergic immune responses are
induced by allergen-speciﬁc Th2 cytokines, such as IL-4 and IL-13,
which promote the secretion of IgG4 and IgE by B cells [39]. Recent
studies indicated that Th2 immune reactions contributed to IgG4-DS
[15,32,40] and IgG4-related tubulointerstitial nephritis [31,41]. The
expression proﬁle of cytokines suggested that IgG4-DS was charac-
terized bya deviation of the Th1/Th2 balance to a Th2phenotype and
elevated expression of Th2 cytokines. Contrary to our results, Ohta
et al. [42] reported a strong predominance of Th1 and cytotoxic type
1 cells in the salivary glands from IgG4-DS patients. They concluded
that disruption of the Th1/Th2 balancemight be due to differences in
the specimens examined or the severity of the disease.
Chemokines are important for leukocyte activation and chemo-
taxis. Interactions between chemokines and chemokine receptors
promote the selective local inﬁltration of speciﬁc cells into inﬂamed
areas. Furthermore, chemokines are intimately involved in main-
tenance of the Th1/Th2 balance and immune responses in cardiac
allograft rejection [43], atopic keratoconjunctivitis [44], and cuta-
neous lupus erythematosus [45]. Chemokines also play a key role in
lymphoid neogenesis in target organs [46]. Immunohistochemical
staining in our studies indicated that Th2-type chemokines
including macrophage-derived chemokine (MDC)/CCL22 and
thymus and activation regulated chemokine (TARC)/CCL17, natural
ligands for CCR4 on Th2 cells, were detectable in and around the
ductal epithelial cells and GCs, while CCR4 was expressed on inﬁl-
trating lymphocytes in LSGs in both SS and IgG4-DS patients. Thus,
interactions of CCR4 with MDC and TARC may play a critical role in
the accumulation of Th2 cells and subsequently, the progression of
SS and IgG4-DS [12,32]. In contrast, interferon gamma induced
protein 10 (IP-10)/CXCL10, natural ligand for CXCR3 on Th1 cells,
was detected in and around the ductal epithelial cells, while CXCR3
was only expressed on inﬁltrating lymphocytes in LSGs from SS
patients [47].
Fig. 1. Histopathological ﬁndings in salivary glands from patients with Sjögren’s syndrome (SS) and IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS). SS is characterized by
periductal lymphocytic inﬁltration with atrophy or severe destruction of the acini, while IgG4-DS shows non-periductal lymphocytic inﬁltration with hyperplastic GCs and mild
destruction of the acini. Abbreviations: GC, germinal center.
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The Th1/Th2 paradigm was recently expanded by the identiﬁ-
cation of Th17 cells, a subset of CD4þ Th cells characterized by theirTable 2
Role of Th subsets in IgG4-related disease (IgG4-RD). Abbreviations: Th, T helper;
MD, Mikulicz’s disease; AID, activation-induced cytidine deaminase; LSG, labial
salivary gland; Tc1, T cytotoxic type 1; Tfh, follicular helper T; NLR, nucleotide-
binding oligomerization domain-like receptor; TLR, Toll-like receptor; AIP, autoim-
mune pancreatitis; BAFF, B-cell activating factor belonging to the tumor necrosis
factor family; APRIL, a proliferation-inducing ligand; Treg, regulatory T; TGF-b,
transforming growth factor b.
Principal ﬁndings Reference
Overexpression of IL-21 by Th2 cells
play a key role in germinal center
formation and IgG4 production in IgG4-DS.
[15]
Peripheral CD4þ T cells from the patient
with MD reveal the deviation of the Th1/Th2 balance to Th2.
[31]
Th2 and regulatory immune reactions
play a key role of IgG4 production in MD.
[32]
The production of IgG4 antibodies appears
to be driven in part by Th2 cytokines that
mediate allergic responses and IgE production.
[38]
Th2 cells are involved in the pathogenesis
of IgG4-related lacrimal gland enlargement.
[39]
Overexpressions of IL-10, TGF-b, and AID
in LSGs play important roles in the pathogenesis
of IgG4-RD, such as IgG4-speciﬁc class-switch
recombination and ﬁbrosis.
[81]
IgG4-related tubulointerstitial nephritis shows
ampliﬁcation of IL-10 and TGF-b.
[41]
Th1 and Tc1 cell populations and IL-17 expression
are involved in the mechanism of pathogenesis
of IgG4-related sclerosing sialadenitis.
[42]
IgG4-related interstitial nephritis shows Tfh cells in
enhancing a skewed B-cell terminal maturation
and of CD20 þ B cells in disease progression.
[66]
Activation of NLR and TLR in monocytes from AIP
patients induces IgG4 production by B cells.
[76]
BAFF and APRIL are useful markers for predicting
disease activity in IgG4-RD.
[78]
The progression and induction of AIP was supported
by increased memory Treg and Th2 immune responses.
[80]ability to produce IL-17. Several studies have reported that IL-17
was detected in epithelial and inﬁltrating mononuclear cells in
LSGs from patients with SS. In addition, Th17 cells are “tissue
seeking” and intimately involved in the initiation of SS [48]. Youi-
nou et al. [49] reported that Th17 cells orchestrate autoreactive GCs.
However, Our previous data in selectively extracted lesions from
LSGs by laser capture microdissection showed that the expressions
of Th17-related molecules in inﬁltrating lymphocytes outside
ectopic GCs were higher than inside ectopic GCs [36]. Interestingly,
a subset of Th17/Th1 cells identiﬁed in the gut of Crohn’s disease
patients may co-express IFN-g and IL-17 [50]. Both Th1 and Th17
cells were involved in the pathogenesis of SS [51], and the early
induction of a CD4þ Th1/Th17 pathway caused the systemic release
of IL-17 in mice [52]. Our previous data suggest that both Th1 and
Th17 cells present around the ductal epithelial cells might be of
critical importance in the initiation of SS. Furthermore, the
destruction of epithelial by Th1 and Th17 cells are thought to play
an important pathogenetic role by the occurrence of inﬁltrating
lesions in various epithelial tissues as well as the increased
epithelial expression of various immunoactive molecules. Thus, SS
has been described as “autoimmune epithelitis” [6]. In contrast,
Th17-related molecules were rarely expressed in patients with
IgG4-DS [32,36]. As mentioned above, IgG4-DS showed non-
periductal lymphocytic inﬁltration and mild destruction of the
epithelial cells. These ﬁndings were speculated that IgG4-DS might
be a “non- autoimmune epithelitis”.
1.3. Regulatory T cells
Treg cells, identiﬁed by the expression of Foxp3, are essential for
the maintenance of immunological self-tolerance and immune
homeostasis to prevent the development of various inﬂammatory
diseases. It achieves this either by direct contact with effector im-
mune cells and/or by secreting anti-inﬂammatory cytokines such as
IL-10 and transforming growth factor (TGF)-b. Treg cells exert their
effects through the modulation of both T and B cell responses. Two
subsets of Treg cells, CD4þ CD25þ Foxp3þ Treg cells [53] and IL-
10eproducing Tr1 cells [54] are crucial for regulating effector T
cell functions. CD4þ CD25þ Foxp3þ Treg cells can prevent
Fig. 2. Unique structure of IgG4 antibody. A, IgG4 antibody consists of two heavy chains and two light chains. B, Fc fragment of IgG4 can interact with the Fc fragment of another
IgG4 molecule. C, Exchange of half-molecules (Fab-arm exchange) results in IgG4 combining two different speciﬁcities in a single molecule (bispeciﬁc antibody).
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defects in Treg cell generation often develop T cell-mediated sys-
temic autoimmune responses that affect multiple organs. Kol-
kowski et al. [56] demonstrated that salivary glands in SS
constitutively expressed IL-10 and TGF-b. Other studies reported a
signiﬁcant reduction of Tregs in LSGs and peripheral blood from SS
patients that might be involved in the pathogenesis of salivary
gland destruction [57,58]. In contrast, Gottenberg et al. [59] re-
ported increased Treg cell numbers in the peripheral blood of SS
patients. Therefore, it is unclear whether Tregs are involved in the
pathogenesis of SS. According to recent data, Foxp3þ T-regulatory
cell frequency in the salivary glands of SS patients correlates with
inﬂammation grade and certain risk factors for lymphoma devel-
opment [60]. While in early and moderate inﬁltrations a compen-
satory control of Tregs in response to Th17 expansion seems to
occur, in advanced SS lesions Tregs may fail to control the immune
mediated tissue injury [7,61]. Increased levels of Treg cells in sali-
vary glands from SS patients might suggest negative feedback is
more active than in healthy subjects. Therefore, Treg cells might be
not involved in the initiation of disease.
Zen et al. [62] reported that signiﬁcant numbers of CD4þ CD25þ
Foxp3þ Tregs inﬁltrated the affected tissues in cases of autoim-
mune pancreato-cholangitis (AIPC), which is one of IgG4-RD.
Furthermore, another study demonstrated that IL-10 decreased IL-
4-induced IgE switching but increased IL-4-induced IgG4 produc-
tion [63]. We found that IL-4, IL-10, and Foxp3 were positively
correlated with the IgG4/IgG ratio in the salivary glands from pa-
tients with IgG4-DS [32]. These results suggest that Th2 and reg-
ulatory immune reactions might play key roles in IgG4 production.
2. Role of IL-21 in SS and IgG4-DS
2.1. Follicular helper T cells
Tfh cells were recently identiﬁed as a unique Th phenotype,
expressing high levels of CXCR5, a chemokine receptor [64].
Several studies reported that Tfh cells control the functionalactivity of effector Th cells and promote ectopic GC formation by
IL-21, which contributed to impaired B cell differentiation [65,66].
Once GCs are formed, Tfh cells are required for their maintenance
and the regulation of B cell differentiation into plasma cells and
memory B cells. Several studies in SS patients demonstrated that
IL-21 was increased in serum and high levels of IL-21 receptor
were present on the surface of most B cells [67]. Furthermore, IL-
4 and IL-21 receptors knockout mice have greatly reduced IgG
responses, indicating that IL-21 co-operates with IL-4 to regulate
humoral immune responses [68]. We previously observed that
Tfh-related molecules, CXCR5 and B-cell lymphoma 6 protein
(Bcl-6), were highly expressed on inﬁltrating lymphocytes in
ectopic GCs of LSG lesions from both SS and IgG4-DS patients
[15,36]. These results provide strong support for Tfh cells in the
progression of disease as a lymphoproliferative disorder, partic-
ularly in the growth and activation of ectopic GC formation
(Fig. 3).
IL-21 was mainly produced by Th2 and Th17 cells in addition
to Tfh cells [68,69]. Interestingly, high IL-21 expression was only
detected outside ectopic GCs in patients with IgG4-DS in our
immunohistological analyses. The expression patterns of Th2-
related molecules (IL-4, CCR4 and c-Maf) in LSGs were similar
to that of IL-21 in patients with IgG4-DS. In contrast, Th17-related
molecules were rarely expressed in patients with IgG4-DS.
Furthermore, IL-21 positively correlated with the number of GCs
formed in LSGs from patients with IgG4-DS [15]. Taken together,
these ﬁndings suggest that excessive IL-21 production by Th2
cells in salivary glands from IgG4-DS patients might induce Bcl-6
expression in B cells resulting in multiple GC formation.
Furthermore, IL-21 directly inhibited IL-4-induced IgE production
[70], and IgG4 class switching was induced by co-stimulation
with IL-4 and IL-21 in humans and mice [71]. In addition, IL-21
induced IL-10 production by mitogen-stimulated peripheral
blood mononuclear cells in humans [72]. Therefore, we speculate
that IL-21 correlates with IL-4 and IL-10 for IgG4 class switching.
In the current study, we found that IL-21 positively correlated
with the IgG4/IgG ratio in immunohistochemically positive cells
Fig. 3. Schematic model of Th cell network in SS. Th1 and Th17 cells are involved in early stages of disease, while Th2 and Tfh cells are associated with GC formation in the late stage.
Abbreviations: Th, T helper; Tfh, follicular helper T.
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switching of IgG4 in IgG4-DS [73].
2.2. Innate immunity in IgG4-DS
Macrophages act as cells in the immune response to foreign
invaders of the body, by presenting pathogenic antigens to antigen-
speciﬁc Th cells. Historically, they have been classiﬁed into two
distinct macrophage phenotypes, “classically activated” proin-
ﬂammatory (M1) and “alternatively activated” anti-inﬂammatory
(M2) macrophages [74]. M2 macrophages are activated by IL-4,Fig. 4. Schematic model of Th cell and innate immune network in IgG4-DS. Th2, Treg, an
macrophages promote Th2 immune reaction by IL-33 as well as BAFF and APRIL. Abbreviat
factor family; APRIL, a proliferation-inducing ligand.produce high levels of IL-10 and are important for debris scav-
enging, wound healing and ﬁbrosis. These polarized macrophage
populations can also contribute to systemic diseases [75]. Wata-
nabe et al. [76] demonstrated that abnormal innate immune re-
sponses induced via Toll-like receptor signaling in macrophages
might enhance Th2 immune responses and the immunopatho-
genesis of IgG4-RD. Our current studies observed that IgG4-DS
patients showed predominant inﬁltration by M2 macrophages
that secreted IL-10 and IL-13 in salivary glands.
Dendritic cells (DCs) are professional antigen presenting
cells that bridge innate and adaptive immunity. Expression ofd Tfh cells play key roles in GC formation and IgG4 production. Dendritic cells and
ions: Treg, regulatory T; BAFF, B cell activating factor belonging to the tumor necrosis
M. Moriyama et al. / Journal of Autoimmunity 51 (2014) 81e8886DC-derived TNF-family ligands such as a proliferation-inducing
ligand (APRIL) and B cell activating factor belonging to the tumor
necrosis factor family (BAFF) is induced by innate immune signals
to promote the differentiation and activation of plasma cells [77]. In
IgG4-RD patients, serum BAFF and APRIL levels were signiﬁcantly
higher than in healthy individuals [78]. BAFF and APRIL may
contribute to progressive plasmacyte inﬁltration and ectopic GC
formation in the target organs of patients with IgG4-RD. In addi-
tion, BAFF and APRIL enhance IgG4 and IgE class switching in the
presence of IL-4 [79]. Th2 cytokine production was increased in the
tissues of patients with autoimmune pancreatitis [80]. Therefore,
BAFF and APRIL may contribute to the pathogenesis of IgG4-RD in
concert with Th2 cells. Although IgG4-RD was considered to be a
Th2-dependent disease [40,41,81], the mechanism of Th2 polari-
zation has yet to be elucidated. IL-33 is a recently identiﬁed cyto-
kine that directly stimulates ST2, IL-33 receptor, expressed by Th2
cells to produce IL-4, IL-5, and IL-13 [82]. Moreover, the genetic
polymorphism of IL-33 in humans is associated with allergic dis-
eases [83]. Our current studies suggest that IL-33 production by DCs
and M2 macrophages might play a key role in Th2 cytokine pro-
duction and the pathogenesis of IgG4-DS (Fig. 4).
3. Conclusions
Research accumulated in recent years makes it increasingly
clear that the immunological backgrounds are entirely different
between SS and IgG4-DS. However, additional research is required
to elucidate further the pathogenesis of IgG4-DS, especially the
development of a mouse model of IgG4-DS. Although Glucocorti-
coids are the standard treatment for IgG4-RD, Yamamoto et al. [84]
reported that the relapse rate of IgG4-DS during steroid therapy is
26.8%. Amore thorough understanding of the complexmechanisms
of IgG4-DS, especially the role of Th subset-related cytokines, could
lead to the development of novel pharmacological strategies aimed
at disrupting the cytokine network and inhibiting the initiation
and/or progression of IgG4-DS. Finally, it should be noted that while
this thesis focuses primarily on Tcells, that there have recently been
other extensive reviews and hypotheses published on Sjogren’s
syndrome, reﬂecting its increased interest not only to basic im-
munologists, but also to rheumatologists [4,85e116].
Competing interests
The authors declare no competing interests.
Author contributions
All authors provided substantial contributions to discussions of
content, and to reviewing and editing the manuscript before sub-
mission. M Moriyama researched the data and wrote the article.
Acknowledgments
This work was supported by the “Research on Measures for
Intractable Diseases” Project, a matching fund subsidy from the
Ministry of Health Labour and Welfare, Japan.
References
[1] Youinou P. Sjogren’s syndrome: a quintessential B cell-induced autoimmune
disease. Jt Bone Spine 2008;75:1e2.
[2] Gershwin ME. The mosaic of autoimmunity. Autoimmun Rev 2008;7:161e3.
[3] Adamson 3rd TC, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis
of lymphoid inﬁltrates in primary Sjogren’s syndrome using monoclonal
antibodies. J Immunology (Baltimore, Md 1950) 1983;130:203e8.[4] Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjog-
ren’s syndrome: what we know and what we should learn. J Autoimmun
2012;39:4e8.
[5] Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clin
Immunol Immunopathol 1994;72:162e5.
[6] Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The role of epithelial cells in
the initiation and perpetuation of autoimmune lesions: lessons from Sjog-
ren’s syndrome (autoimmune epithelitis). Lupus 2006;15:255e61.
[7] Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren’s syn-
drome. Autoimmun Rev 2010;9:A305e10.
[8] King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and
dysregulated immune responses. Annu Rev Immunol 2008;26:741e66.
[9] Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O,
et al. The Th1/Th2 cytokine balance changes with the progress of the
immunopathological lesion of Sjogren’s syndrome. Clin Exp Immunol
2002;128:562e8.
[10] Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T,
et al. Cytokine messenger RNA expression in the labial salivary glands of
patients with Sjogren’s syndrome. Arthritis Rheum 1996;39:1376e84.
[11] van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, Knol E, Bihari IC,
Jacobs JW, et al. Salivary gland and peripheral blood T helper 1 and 2 cell
activity in Sjogren’s syndrome compared with non-Sjogren’s sicca syndrome.
Ann Rheum Dis 2005;64:1474e9.
[12] Moriyama M, Hayashida JN, Toyoshima T, Ohyama Y, Shinozaki S, Tanaka A,
et al. Cytokine/chemokine proﬁles contribute to understanding the patho-
genesis and diagnosis of primary Sjogren’s syndrome. Clin Exp Immunol
2012;169:17e26.
[13] Morgan WS, Castleman B. A clinicopathologic study of Mikulicz’s disease. Am
J Pathol 1953;29:471e503.
[14] M.Moriyama, A.Tanaka, T.Maehara, Y.Ohyama, M.Shimizu, H.Nakashima, et-
al. Clinical characteristics of Mikulicz’s disease as an IgG4-related disease.
Clin Oral Investig. in press.
[15] Maehara T, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Tanaka A,
et al. Interleukin-21 contributes to germinal centre formation and immu-
noglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis,
so-called Mikulicz’s disease. Ann Rheum Dis 2012;71:2011e20.
[16] Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological char-
acteristics of Mikulicz’s disease (IgG4-related plasmacytic exocrinopathy).
Autoimmun Rev 2005;4:195e200.
[17] Yamamoto M, Takahashi H, Naishiro Y, Isshiki H, Ohara M, Suzuki C, et al.
Mikulicz’s disease and systemic IgG4-related plasmacytic syndrome (SIPS).
Nihon Rinsho Meneki Gakkai Kaishi 2008;31:1e8.
[18] Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H,
et al. A new conceptualization for Mikulicz’s disease as an IgG4-related
plasmacytic disease. Mod Rheumatol 2006;16:335e40.
[19] Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High
serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J
Med 2001;344:732e8.
[20] Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, et al. IgG4-
related sclerosing cholangitis with and without hepatic inﬂammatory
pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis:
do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol
2004;28:1193e203.
[21] Takeda S, Haratake J, Kasai T, Takaeda C, Takazakura E. IgG4-associated
idiopathic tubulointerstitial nephritis complicating autoimmune pancrea-
titis. Nephrol Dial Transplant 2004;19:474e6.
[22] Hamed G, Tsushima K, Yasuo M, Kubo K, Yamazaki S, Kawa S, et al. In-
ﬂammatory lesions of the lung, submandibular gland, bile duct and prostate
in a patient with IgG4-associated multifocal systemic ﬁbrosclerosis. Respir-
ology 2007;12:455e7.
[23] Kitagawa S, Zen Y, Harada K, Sasaki M, Sato Y, Minato H, et al. Abundant
IgG4-positive plasma cell inﬁltration characterizes chronic sclerosing siala-
denitis (Kuttner’s tumor). Am J Surg Pathol 2005;29:783e91.
[24] Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al.
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and
details. Mod Rheumatol 2012;22:1e14.
[25] Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:
539e51.
[26] Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al.
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). Mod
Rheumatol 2011;2012(22):21e30.
[27] Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R,
et al. Recommendations for the nomenclature of IgG4-related disease and its
individual organ system manifestations. Arthritis Rheum 2012;64:3061e7.
[28] van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-
Martinez P, Vermeulen E, et al. Anti-inﬂammatory activity of human IgG4
antibodies by dynamic Fab arm exchange. Sci (New York, NY) 2007;317:
1554e7.
[29] Rispens T, Ooievaar-De Heer P, Vermeulen E, Schuurman J, van der Neut
Kolfschoten M, Aalberse RC. Human IgG4 binds to IgG4 and conformationally
altered IgG1 via Fc-Fc interactions. J Immunology (Baltimore, Md 1950)
2009;182:4275e81.
[30] Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al.
Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and
CD23 expression by human B cells. Proc Natl Acad Sci U S A 1993;90:3730e4.
M. Moriyama et al. / Journal of Autoimmunity 51 (2014) 81e88 87[31] Miyake K, Moriyama M, Aizawa K, Nagano S, Inoue Y, Sadanaga A, et al.
Peripheral CD4þ T cells showing a Th2 phenotype in a patient with Miku-
licz’s disease associated with lymphadenopathy and pleural effusion. Mod
Rheumatol 2008;18:86e90.
[32] Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T,
et al. Th2 and regulatory immune reactions contribute to IgG4 production
and the initiation of Mikulicz disease. Arthritis Rheum 2012;64:254e63.
[33] Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA
expression in the central nervous system of mice with experimental auto-
immune encephalomyelitis reveals that IL-10 mRNA expression correlates
with recovery. J Immunology (Baltimore, Md 1950) 1992;149:2496e505.
[34] Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al.
Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the
onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87e99.
[35] Ozaki Y, Amakawa R, Ito T, Iwai H, Tajima K, Uehira K, et al. Alteration of
peripheral blood dendritic cells in patients with primary Sjogren’s syndrome.
Arthritis Rheum 2001;44:419e31.
[36] Maehara T, Moriyama M, Hayashida JN, Tanaka A, Shinozaki S, Kubo Y, et al.
Selective localization of T helper subsets in labial salivary glands from pri-
mary Sjogren’s syndrome patients. Clin Exp Immunol 2012;169:89e99.
[37] Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R,
et al. Lymphoid organisation in labial salivary gland biopsies is a possible
predictor for the development of malignant lymphoma in primary Sjogren’s
syndrome. Ann Rheum Dis 2011;70:1363e8.
[38] Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the
biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011;23:
119e24.
[39] Finkelman FD, Boyce JA, Vercelli D, Rothenberg ME. Key advances in
mechanisms of asthma, allergy, and immunology in 2009. J Allergy Clin
Immunol 2010;125:312e8.
[40] Tsuboi H, Matsuo N, Iizuka M, Tsuzuki S, Kondo Y, Tanaka A, et al. Analysis of
IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res
Ther 2012;14:R171.
[41] Nakashima H, Miyake K, Moriyama M, Tanaka A, Watanabe M, Abe Y, et al.
An ampliﬁcation of IL-10 and TGF-beta in patients with IgG4-related tubu-
lointerstitial nephritis. Clin Nephrol 2010;73:385e91.
[42] Ohta N, Makihara S, Okano M, Kurakami K, Ishida A, Furukawa T, et al. Roles
of IL-17, Th1, and Tc1 cells in patients with IgG4-related sclerosing siala-
denitis. Laryngoscope 2012;122:2169e74.
[43] OberbarnscheidtMH,Walch JM, Li Q,WilliamsAL,Walters JT,HoffmanRA, et al.
Memory T cells migrate to and reject vascularized cardiac allografts indepen-
dent of the chemokine receptor CXCR3. Transplantation 2011;91:827e32.
[44] Yamagami S, Ebihara N, Amano SY. Chemokine receptor gene expression in
giant papillae of atopic keratoconjunctivitis. Mol Vis 2005;11:192e200.
[45] Gambichler T, Genc Z, Skrygan M, Scola N, Tigges C, Terras S, et al. Cytokine
and chemokine ligand expression in cutaneous lupus erythematosus. Eur J
Dermatol 2012;22:319e23.
[46] Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J, et al.
Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on
endothelial cells and within lymphoid follicles contributes to the establish-
ment of germinal center-like structures in Sjogren’s syndrome. Arthritis
Rheum 2001;44:2633e41.
[47] Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-
gamma-induced T cell-attracting chemokines, interferon-gamma-inducible
10-kd protein (CXCL10) and monokine induced by interferon-gamma
(CXCL9), in the salivary gland lesions of patients with Sjogren’s syndrome.
Arthritis Rheum 2002;46:2730e41.
[48] Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic
effect of interleukin-17A in induction of Sjogren’s syndrome-like disease
using adenovirus-mediated gene transfer. Arthritis Res Ther 2010;12:R220.
[49] Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren’s syndrome.
Arthritis Res Ther 2011;13:227.
[50] McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W,
McClanahan T, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-
10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol
2007;8:1390e7.
[51] Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identiﬁcation of IL-18
and Th17 cells in salivary glands of patients with Sjogren’s syndrome, and
ampliﬁcation of IL-17-mediated secretion of inﬂammatory cytokines from
salivary gland cells by IL-18. J Immunology (Baltimore, Md 1950) 2008;181:
2898e906.
[52] Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression
of interleukin-23 and interleukin-17 in Sjogren’s syndrome: ﬁndings in
humans and mice. Arthritis Rheum 2008;58:734e43.
[53] Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM.
The lifestyle of naturally occurring CD4þ CD25þ Foxp3þ regulatory T cells.
Immunol Rev 2006;212:60e73.
[54] Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity.
Semin Immunol 2011;23:202e8.
[55] Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, et al. Liver-
targeted and peripheral blood alterations of regulatory T cells in primary
biliary cirrhosis. Hepatology 2006;43:729e37.
[56] Kolkowski EC, Reth P, Pelusa F, Bosch J, Pujol-Borrell R, Coll J, et al. Th1
predominance and perforin expression in minor salivary glands from pa-
tients with primary Sjogren’s syndrome. J Autoimmun 1999;13:155e62.[57] Li X, Li X, Qian L, Wang G, Zhang H, Wang X, et al. T regulatory cells are
markedly diminished in diseased salivary glands of patients with primary
Sjogren’s syndrome. J Rheumatol 2007;34:2438e45.
[58] Roca V, Calafat M, Larocca L, Ramhorst R, Farina M, Franchi AM, et al. Po-
tential immunomodulatory role of VIP in the implantation sites of predia-
betic nonobese diabetic mice. Reproduction 2009;138:733e42.
[59] Gottenberg JE, Lavie F, Abbed K, Gasnault J, Le Nevot E, Delfraissy JF, et al.
CD4 CD25high regulatory T cells are not impaired in patients with primary
Sjogren’s syndrome. J Autoimmun 2005;24:235e42.
[60] Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM.
Foxp3þ T-regulatory cells in Sjogren’s syndrome: correlation with the grade
of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol
2008;173:1389e96.
[61] Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of
the minor salivary gland inﬁltrates in Sjogren’s syndrome. J Autoimmun
2010;34:400e7.
[62] Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and
regulatory immune reactions are increased in immunoglobin G4-related
sclerosing pancreatitis and cholangitis. Hepatology 2007;45:1538e46.
[63] Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation
of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy
2008;63:1455e63.
[64] Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G,
et al. Human blood CXCR5(þ) CD4(þ) T cells are counterparts of T follicular
cells and contain speciﬁc subsets that differentially support antibody
secretion. Immunity 2011;34:108e21.
[65] Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular
dendritic cells in germinal center B-cell formation and selection. Immunol
Rev 2010;237:72e89.
[66] Zaidan M, Cervera-Pierot P, de Seigneux S, Dahan K, Fabiani B, Callard P, et al.
Evidence of follicular T-cell implication in a case of IgG4-related systemic
disease with interstitial nephritis. Nephrol Dial Transplant 2011;26:2047e50.
[67] Yuan SL, Jiang L, Zhang XL, Li SF, Duan HM, Wang XF. Serum IL-21 level in
patients with primary Sjogren’s syndrome and clinical signiﬁcance of IL-21.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23:124e6.
[68] Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in
regulating immunoglobulin production. Sci (New York, NY) 2002;298:1630e4.
[69] Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, et al.
Interleukin 21 is a T helper (Th) cell 2 cytokine that speciﬁcally inhibits the
differentiation of naive Th cells into interferon gamma-producing Th1 cells.
J Exp Med 2002;196:969e77.
[70] Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, Seto Y, et al. Interleukin 21
prevents antigen-induced IgE production by inhibiting germ line C(epsilon)
transcription of IL-4-stimulated B cells. Blood 2002;100:4565e73.
[71] Kitayama D, Sakamoto A, Arima M, Hatano M, Miyazaki M, Tokuhisa T. A role
for Bcl6 in sequential class switch recombination to IgE in B cells stimulated
with IL-4 and IL-21. Mol Immunol 2008;45:1337e45.
[72] Wood N, Bourque K, Donaldson DD, Collins M, Vercelli D, Goldman SJ, et al.
IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell
Immunol 2004;231:133e45.
[73] Fox RI. The distinct pathogenesis of IgG4 Mickulicz’s disease and Sjogren’s
syndrome in Japan; the role of IL-21 and IL-6. Ann Rheum Dis 2012;71:
1919e20.
[74] Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG.
Identiﬁcation of two distinct macrophage subsets with divergent effects
causing either neurotoxicity or regeneration in the injured mouse spinal
cord. J Neurosci 2009;29:13435e44.
[75] Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional proﬁling of
the human monocyte-to-macrophage differentiation and polarization: new
molecules and patterns of gene expression. J Immunology (Baltimore, Md
1950) 2006;177:7303e11.
[76] Watanabe T, Yamashita K, Fujikawa S, Sakurai T, Kudo M, Shiokawa M, et al.
Involvement of activation of toll-like receptors and nucleotide-binding
oligomerization domain-like receptors in enhanced IgG4 responses in
autoimmune pancreatitis. Arthritis Rheum 2012;64:914e24.
[77] Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B
cell survival. Annu Rev Immunol 2003;21:231e64.
[78] Kiyama K, Kawabata D, Hosono Y, Kitagori K, Yukawa N, Yoshifuji H, et al.
Serum BAFF and APRIL levels in patients with IgG4-related disease and their
clinical signiﬁcance. Arthritis Res Ther 2012;14:R86.
[79] Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs
induce CD40-independent immunoglobulin class switching through BLyS
and APRIL. Nat Immunol 2002;3:822e9.
[80] Okazaki K, Uchida K, Fukui T. Recent advances in autoimmune pancreatitis:
concept, diagnosis, and pathogenesis. J Gastroenterol 2008;43:409e18.
[81] Kanari H, Kagami S, Kashiwakuma D, Oya Y, Furuta S, Ikeda K, et al. Role of
Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy
Immunol 2010;152(Suppl. 1):47e53.
[82] Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-
33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity
2005;23:479e90.
[83] Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, et al.
Association of serum interleukin-33 level and the interleukin-33 genetic
variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875e81.
M. Moriyama et al. / Journal of Autoimmunity 51 (2014) 81e8888[84] Yamamoto M, Takahashi H, Ishigami K, Yajima H, Shimizu Y, Tabeya T, et al.
Evaluation and clinical validity of a new questionnaire for Mikulicz’s disease.
Int J Rheumatol 2012;2012:283459.
[85] Vissink A, Bootsma H, Spijkervet FK, Hu S, Wong DT, Kallenberg CG. Current
and future challenges in primary Sjogren’s syndrome. Curr Pharm Biotechnol
2012;13:2026e45.
[86] Barrera MJ, Bahamondes V, Sepulveda D, Quest AF, Castro I, Cortes J, et al.
Sjogren’s syndrome and the epithelial target: a comprehensive review.
J Autoimmun 2013;42:7e18.
[87] Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. In-
terventions for the management of dry mouth: topical therapies. Cochrane
Database Syst Rev 2011;7:CD008934.
[88] Thabet Y, Le Dantec C, Ghedira I, Devauchelle V, Cornec D, Pers JO, et al.
Epigenetic dysregulation in salivary glands from patients with primary
Sjogren’s syndrome may be ascribed to inﬁltrating B cells. J Autoimmun
2013;41:175e81.
[89] Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun
2013;41:1e5.
[90] Yao Q, Altman RD, Wang X. Systemic lupus erythematosus with Sjogren
syndrome compared to systemic lupus erythematosus alone: a meta-anal-
ysis. J Clin Rheumatol 2012;18:28e32.
[91] Gliozzi M, Greenwell-Wild T, Jin W, Moutsopoulos NM, Kapsogeorgou E,
Moutsopoulos HM, et al. A link between interferon and augmented plasmin
generation in exocrine gland damage in Sjogren’s syndrome. J Autoimmun
2013;40:122e33.
[92] Ebert EC. Gastrointestinal and hepatic manifestations of Sjogren syndrome.
J Clin Gastroenterol 2012;46:25e30.
[93] Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in
primary Sjogren’s syndrome: an overview. J Autoimmun 2012;39:354e8.
[94] Singh N, Cohen PL. The T cell in Sjogren’s syndrome: force majeure, not
spectateur. J Autoimmun 2012;39:229e33.
[95] Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A,
Cardenas-Roldan J, Pineda-Tamayo R, et al. Sjogren’s syndrome at the
crossroad of polyautoimmunity. J Autoimmun 2012;39:199e205.
[96] Scoﬁeld RH. Vasculitis in Sjogren’s syndrome. Curr Rheumatol Rep 2011;13:
482e8.
[97] Arentz G, Thurgood LA, Lindop R, Chataway TK, Gordon tP. Secreted human
Ro52 autoantibody proteomes express a restricted set of public clonotypes.
J Autoimmun 2012;39:466e70.
[98] Agmon-Levin N, Kivity S, Tzioufas AG, Lopez Hoyos M, Rozman B, Efes I, et al.
Low levels of vitamin-D are associated with neuropathy and lymphoma
among patients with Sjogren’s syndrome. J Autoimmun 2012;39:234e9.
[99] Porola P, Mackiewicz Z, Laine M, Baretto G, Stegaev V, Takakubo Y, et al.
Laminin isoform proﬁles in salivary glands in Sjogren’s syndrome. Adv Clin
Chem 2011;55:35e59.[100] Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A.
B cells in Sjogren’s syndrome: from pathophysiology to diagnosis and
treatment. J Autoimmun 2012;39:161e7.
[101] Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjogren syndrome pa-
tients according to serological proﬁles. J Autoimmun 2012;39:15e26.
[102] Sim S, Wolin SL. Emerging roles for the Ro 60-kDa autoantigen in noncoding
RNA metabolism. Wiley Interdiscip Rev RNA 2011;2:686e99.
[103] Seror R, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, et al.
J Autoimmun 2012;39:97e102.
[104] Fischer M, Horn IS, Bertolini J, Dietzsch S, Fuchs M, Dietz A. Laryngeal MALT
lymphoma with known Sjogren syndrome 2011;59:111e4.
[105] Tzioufas AG, Vlachoyiannopoulos PG. Sjogren’s syndrome: an update
on clinical, basic and diagnostic therapeutic aspects. J Autoimmun
2012;39:1e3.
[106] Guerrier T, Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P. Role of
toll-like receptors in primary Sjogren’s syndrome with a special emphasis on
B-cell maturation within exocrine tissues. J Autoimmun 2012;39:69e76.
[107] Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-
cell depletion therapy in patients with primary Sjogren’s syndrome.
J Autoimmun 2012;39:103e11.
[108] Takahashi H, Yamamoto M, Tabeya T, Suzuki C, Naishiro Y, Shinomura Y,
et al. The immunobiology and clinical characteristics of IgG4 related diseases.
J Autoimmun 2012;39:93e6.
[109] Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoim-
mune disease. Nat Rev Rheumatol 2009;5:433e41.
[110] Sarkar PK, Patel N, Furie RA, Talwar A. Pulmonary manifestations of primary
Sjogren’s syndrome. Indian J Chest Dis Allied Sci 2009;51:93e101.
[111] Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM,
Tzioufas AG, et al. Peripheral neuropathies in Sjogren’s syndrome: a critical
update on clinical features and pathogenetic mechanisms. J Autoimmun
2012;39:27e33.
[112] Manoussakis MN, Tsinti M, Kapsogeorgou EK, Moutsopoulos HM. The sali-
vary gland epithelial cells of patients with primary Sjogren’s syndrome
manifest signiﬁcantly reduced responsiveness to 17b-estradiol. J Autoimmun
2012;39:64e8.
[113] Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, et al. Sex
steroids in Sjogren’s syndrome. J Autoimmun 2012;39:49e56.
[114] Ramirez M, Ramos-Casals M, Graus F. Central nervous system involvement in
primary Sjogren syndrome. Med Clin (Barc) 2009;133:349e59.
[115] Brito-Zeron P, Retamozo S, Gandia M, Akasbi M, Perez-De-Lis M, Diaz-
Lagares C, et al. Monoclonal gammopathy related to Sjogren syndrome: a key
marker of disease prognosis and outcomes. J Autoimmun 2012;39:43e8.
[116] Ice JA, Li H, Adrianto I, Lin PC, Kelly JA, Montgomery CG, et al. Genetics of
Sjogren’s syndrome in the genome-wide association era. J Autoimmun
2012;39:57e63.
